Trends Biotechnol December 2018 PMID 30220578

The Open Insulin Project: A Case Study for 'Biohacked' Medicines.

Jenna E Gallegos, Christopher Boyer, Eleanore Pauwels, Warren A Kaplan, Jean Peccoud

Full text PDF Download social card

Mentions

Peak: 4 in Jul 2021

across 5 sources since Apr 2019

Extended reach

4,944

potential audience

Total likes

Video views

Mentions per month

Apr 2019 – Jul 2021

Where it's discussed

News15 articles
Facebook5 posts
Blogs5 articles
X / Twitter4 posts
YouTube4 videos

AI synopsis

What people are saying

Discussions express support for the idea that regulatory barriers, rather than patents, are the main obstacle to insulin innovation, as seen in the mention that the problem involves the FDA and insurance companies. Some participants demonstrate interest by referencing accessible scientific journals and the potential for biohacking, reflecting a desire for broader understanding. The tone balances critique with encouragement for alternative approaches, using words like 'thinking and acting differently' and 'more boldly' to convey enthusiasm and a call for change.

AgreementModerate agreement

Most discussions acknowledge the critique of regulatory and patent systems, with some supporting the idea that the problem lies with institutions like the FDA and insurance companies rather than patents themselves.

InterestHigh interest

The topic of open-source insulin production and biohacking sparks high curiosity, especially with mentions of accessing scientific journals and the potential for innovative approaches.

EngagementModerate engagement

Participants reference specific concepts such as biohacking, insulin manufacturing, and legal hurdles, indicating a moderate level of involved discussion, but not extremely deep or technical engagement.

ImpactModerate impact

While the discussions highlight significant issues like drug affordability and regulation, they mainly focus on raising awareness and advocating for changes rather than directly influencing policy or practice.

Abstract in brief

The Open Insulin Project aims to create open-source methods for insulin production to make it cheaper and less dependent on patents, challenging traditional drug development models.
Despite its innovative approach, the project faces major hurdles because US regulations focus more on preventing unsafe drugs rather than controlling patents, which complicates legal approval for homemade or alternative insulin sources.
If successful, the project could lead to new ways for individuals or small groups to produce insulin at home, forcing regulators to reconsider how they ensure drug safety and affordability in a future where traditional pharmaceuticals remain expensive.]

Read the full abstract

All mentions

Open Source Insulin Production and Biohacking Advances

The Open Insulin Project aims to develop open-source methods for affordable insulin production, challenging traditional models. Despite regulatory challenges focusing on safety, its success could revolutionize…

Aranea Science · Jul 28, 2021 23 views

Open Source Insulin Development and Biohacked Medical Solutions

The Open Insulin Project aims to create accessible, open-source insulin production methods, challenging patent restrictions and traditional drug development. Despite regulatory hurdles, success could revolutionize…

Aranea Science · Jul 27, 2021 14 views

Open Source Insulin: Innovating Diabetes Treatment and Access

The Open Insulin Project aims to develop open-source insulin production methods to reduce costs and dependency on patents. Despite regulatory challenges, success could enable home-based insulin synthesis, prompting a…

Aranea Science · Jul 27, 2021 12 views

Open-Source Insulin Development and Regulatory Challenges

The Open Insulin Project aims to produce affordable insulin through open-source methods, challenging traditional drug models. The project faces hurdles due to US regulations focused on safety rather than patent issues…

Aranea Science · Jul 28, 2021 9 views

Not today Satan

@Roq44 · X

@ctr477 @AOC an old fashioned needle and syringe is not patented the problem here is with the FDA and the insurance companies, not patents https://t.co/bzgTlU7alv

May 5, 2021 · 414 followers View post →

Omar Cheema

@Vivantive · X

Healthare innovation for our times - thinking and acting differently, more boldly - #insulin manufacturing: https://t.co/EXH0CgNtmc

Jun 9, 2019 · 984 followers View post →

Mohawk College Library

@mohawklibrary · X

Jun 4, 2019 · 1,447 followers View post →

Jean Peccoud

@peccoud · X

@alexisohanian And a link to the peer-reviewed article https://t.co/LCgM8csOus

Apr 8, 2019 · 2,043 followers View post →